Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ralph Lauren Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Ralph Lauren Corp trades at $385.59 (market cap $23.53B). The key difference: Ralph Lauren Corp is far larger — about 5.2× ACADIA Pharmaceuticals Inc.'s market cap, and Ralph Lauren Corp pays a 0.95% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | RL | |
|---|---|---|
Market Cap | $4.49B | $23.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $414.25 |
52-Week Low | $20.06 | $283.34 |
Enterprise Value | $3.69B | $24.47B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Ralph Lauren (RL) trades at $395.31, down 0.73% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.80 surpassing expectations. Revenue growth accelerated to $7.08 billion in 2025, while net income margin improved to 10.49%. Analyst consensus remains strongly bullish with a $446.25 price target, representing 13% upside potential from current levels.
RL presents a compelling growth story with expanding margins and strategic initiatives driving performance. Key risks include consumer discretionary spending sensitivity and competitive pressures in the apparel sector. The company's digital expansion and Next Great Chapter strategy provide catalysts for continued outperformance, though macroeconomic headwinds could impact near-term results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
